[Successful treatment with bortezomib for a patient with plasma cell leukemia accompanied by severe hyperbilirubinemia].

Tatsuji Mino, Akira Sakai, Miki Kinoshita, Tetsumi Yoshida, Keiichiro Mihara, Jun Imagawa, Akiro Kimura

Research output: Contribution to journalArticlepeer-review


A 59-year-old woman was admitted to our hospital with jaundice, renal dysfunction, anemia and hypercalcemia. Primary plasma cell leukemia (PCL) was diagnosed based on findings of IgA-λ type M-protein, 22% plasma cells in the bone marrow and 23.1% plasma cells of WBC in the peripheral blood. Because the total bilirubin (T.Bil) level increased even after the administration of prednisolone (PSL), dexamethasone and methylprednisolone, the patient was started on bortezomib (0.7 mg/m(2) on days 1, 4, 8 and 11 for 3 weeks) combined with PSL (40 mg/day). The level of T.Bil decreased and the patient's condition remarkably improved. We then increased the dose of bortezomib to 1.0 mg/m(2) in the second course, but discontinued treatment just after starting the third course because NCI-CTCAE Grade 3 peripheral neuropathy developed. According to the criteria of the International Myeloma Working Group, the response category was VGPR (=very good partial response) at 1 month after pausing treatment. We recommend these novel agents for PCL, which is an aggressive form of extramedullary plasma cell cancer.

Original languageEnglish
Pages (from-to)92-96
Number of pages5
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Issue number1
Publication statusPublished - 01-2012

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of '[Successful treatment with bortezomib for a patient with plasma cell leukemia accompanied by severe hyperbilirubinemia].'. Together they form a unique fingerprint.

Cite this